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For more than 50 years lidocaine has been used to treat ventricular arrhythmias. Neurologic dysfunction, 
manifested as a stroke, occurred acutely in an 87-year-old woman after she had been administered 
repeated doses of lidocaine, a lidocaine infusion, then an intravenous amiodarone infusion for ventricular 
tachycardia. This was ultimately diagnosed as lidocaine toxicity with a serum lidocaine level of 7.9 mg/L 
(1.5 - 6.0 mg/L). We discuss lidocaine toxicity and risk factors leading to its development, which include 
particularly hepatic dysfunction, cardiac dysfunction, advanced age and other drug administration.
[West J Emerg Med. 2009;10(4):292-294.]
INTRODUCTION
Sudden cardiac death, most commonly caused by 
ventricular tachycardia or fibrillation, affects over half a 
million people in the United States each year.1 Intravenous 
lidocaine has been administered for the treatment of 
ventricular arrhythmias for over 50 years and is still 
commonly used to treat these arrhythmias, although it is no 
longer considered first line therapy.2 Newer antiarrhythmics 
are replacing lidocaine for many indications and are 
sometimes concomitantly administered with potential drug 
interactions. If prescribers are aware of the presentation of 
lidocaine toxicity and its precipitants they can better avoid 
complications. We describe a patient in whom a lidocaine 
bolus and drip successfully abolished ventricular arrhythmias 
who was then administered concurrent amiodarone. This 
precipitated severe neurologic deterioration suggesting stroke. 
We will review the dosing, metabolism, and other factors that 
contribute to decreased metabolism of lidocaine with severe 
neurologic toxicity.
CASE REPORT
Near midday an 87-year-old woman activated 911 
complaining of shortness of breath. The patient’s past 
history was significant for myocardial infarction. A recent 
echocardiogram showed left ventricular hypokinesis 
consistent with an ischemic cardiomyopathy with an ejection 
fraction of 20 to 25%. Previous magnetic resonance imaging 
showed a 9x11x16 mm meningioma, without metastasis, 
edema or hydrocephalus. Her medications included verapamil, 
timolol, and diazepam. 
The initial assessment by paramedics at 1320 described 
an alert and appropriate patient with pupils equal, round and 
reactive; the breathing was not labored, lungs were clear, and 
finger stick glucose was 139. The rhythm was ventricular 
tachycardia. Paramedics gave 50mg lidocaine intravenous 
(IV) push, with resolution of the tachycardia to a narrow 
complex sinus rhythm at a rate of 80 beats per minute. The 
rhythm was stable for one to two minutes, then recurred. 
They administered a second dose of lidocaine 50mg IV push, 
resulting in resolution of the tachycardia to a sinus rate of 78 
beats per minute. The patient reported a decrease in shortness 
of breath and some mild dizziness. Paramedic personnel 
initiated a lidocaine drip at 2mg/minute for transport to the 
emergency department (ED).
In the primary ED, 28 minutes later, the patient had 
a ventricular rate of 152 beats per minute. She received a 
third 50mg dose of lidocaine IV. Her electrocardiogram 
(EKG) revealed normal sinus rhythm with left ventricular 
hypertrophy and an anteroseptal infarct of indeterminate age. 
At 1413 the physician increased the lidocaine drip to 4mg/
minute, and administered aspirin 325mg by mouth. Shortly 
thereafter, the patient received a loading dose of amiodarone 
150mg IV, followed by an amiodarone drip at 1mg/minute. 
She then came via EMS to our hospital.
En route emergency medical service personnel noted 
the patient to be in normal sinus rhythm with ventricular 
ectopy. The lidocaine drip remained at 4mg/minute and the 
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amiodarone failed 20 minutes into the transfer and the 
medication discontinued. During transfer the report notes that 
the patient complained of “being sleepy” but was alert and 
appropriate. Six minutes prior to arrival the patient’s mental 
status changed abruptly. She became non-verbal, her eyes 
remained open with a fixed gaze, but she was able to flex her 
hands on command. 
Upon arrival to our ED the patient’s vitals signs were: 
heart rate 76 beats/min, respiratory rate 22 per minute, 
blood pressure 135/65, tympanic temperature 96.4°F, and 
oxygen saturation 92% on 15-liter flow nonrebreather mask. 
Her weight was 49 kilograms. Her airway was patent. The 
EKG monitor showed normal sinus rhythm. The patient 
was unresponsive to painful stimuli with pupils 4mm and 
nonreactive with intact gag reflex. Plantar reflexes were 
neutral. Given the patient’s abrupt change in mental status, 
brainstem stroke was considered and we consulted neurology. 
We ordered an expedited computerized tomographic scan (CT) 
of the head 19 minutes after arrival. Two minutes later she 
received 0.4mg naloxone intraveniously and the lidocaine drip 
was discontinued. The patient’s National Institute of Health 
(NIH) stroke score was 24, indicating severe neurologic 
impairment.
Initial imaging studies included a chest x-ray with the 
only abnormality being an enlarged cardiac silhouette. CT 
scan of the head revealed mild microvascular ischemic 
changes. An 11 mm partially calcified right falcine mass 
was consistent with a stable meningioma. CT angiography 
examination in the ED 51 minutes after arrival demonstrated 
no evidence of vaso-occlusive change affecting the cervical 
or intracranial arterial vessels. Laboratory values drawn 
19 minutes after arrival at our facility were as follows: 
Sodium 135 mmol/L, potassium 3.7 mmol/L, chloride 103 
mmol/L, bicarbonate 19 mmol/L, creatinine 0.7 mg/dL, blood 
urea nitrogen 19 mg/dL, glucose 164 mg/dL, Mg 1.6 mg/
dL, phosphorus 4.8 mg/dL, ionized calcium 1.10 mmol/L 
(reference 1.17-1.33 mmol/L). Cardiac enzymes, creatinine 
kinase (CK), CKMB and Troponin-T were normal. The 
initial arterial blood gas obtained on room air showed a 
pH of 7.28; the pCO2 was 44 mmHg, pO2 63 mmHg, and 
oxygen saturation 87%. The serum lidocaine level drawn 51 
minutes after arrival, 30 minutes after the lidocaine drip was 
discontinued, resulted 7.9 mg/L with a reference range in our 
laboratory of 1.5-6.0 mg/L.
Following termination of the lidocaine drip the patient’s 
mental status gradually and steadily improved. By 60 minutes 
after termination of the drip her NIH stroke scale score was 
three, indicative of minimal impairment. During the ensuing 
hospitalization no more abnormalities of mental status or other 
neurologic complaints were encountered.
DISCUSSION
Lidocaine is a class Ib anti-arrhythmic drug used 
intravenously for ventricular dysrhythmias and subcutaneously 
for local anesthesia. The 2005 (most recent) guidelines of 
the American Heart Association suggest that it is a second 
line drug after amiodarone for ventricular arrhythmia. 
Amiodarone is now the primary recommendation for medical 
cardioversion because it is believed that aqueous amiodarone 
is more effective than lidocaine in the treatment of shock-
resistant ventricular tachycardia. An alternative treatment is 
intravenously administered lidocaine.2
The two major categories of the adverse effects of 
lidocaine are neurologic and cardiac, with the former being 
more common. Lidocaine’s mechanism of action is depression 
of neuronal excitability by blockage of voltage-dependent 
sodium channels in the cell membrane. This produces the 
therapeutic effects of myocardial stabilization and local 
anesthesia and causes lidocaine’s toxicity.3 Neurologic 
manifestations include paresthesias, confusion, dizziness, 
and respiratory depression, which can progress to psychosis, 
loss of consciousness and seizure. Cardiac manifestations 
of lidocaine toxicity are many, including dysrhythmia, sinus 
bradycardia, and QRS widening.4 There have also been reports 
of sino-atrial node suppression by lidocaine particularly in 
conjunction with other sodium channel blockers such as 
phenytoin. Toxicity may be associated with cardiovascular 
collapse and complete loss of blood pressure, even in younger 
patients.4 The atrioventricular node can be adversely affected 
by inadvertent overdose. Severe bradycardia and asystole have 
been described in patients with myocardial infarction and in 
patients with high grade atrioventricular block.5 
Initial doses of lidocaine range from 0.5 up to 1.5 mg/kg. 
One may repeat 0.5 to 0.75 mg/kg every five to 10 minutes 
to a maximum total dose of 3 mg/kg. In the patient with 
normal hepatic function, maintenance infusion of 1 to 4 mg/
min should be initiated.2 This administration is necessary due 
to lidocaine’s biphasic elimination with an initial half-life of 
approximately seven to 30 minutes (due to plasma protein 
binding and redistribution into adipose and muscle tissue) and 
a terminal half-life of approximately 1.5 to two hours which 
is prolonged with alterations in liver function. The parent 
compound is rapidly metabolized in the liver by dealkylation 
to active metabolites, monoethylglycine xylidide (more toxic 
than the parent compound) and glycine xylidide which have 
extended half-lives of two and 10 hours.4 This may account 
for prolonged neurologic symptoms. Less than 10% is 
excreted in the urine, so a history of renal failure or dialysis do 
not alter ED dosing.
At the time our patient’s mental status was recognized 
to be a manifestation of lidocaine toxicity and when the 
lidocaine drip stopped, the patient had received a total of 811 
mg of lidocaine in three hours and 20 minutes, a total dose 
of approximately 13 mg/kg over two half-lives of the drug. 
Similar impairments have been reported with larger doses of 
lidocaine over shorter periods.5
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Pfeifer et al.6 looked at 750 recipients of intravenous 
lidocaine. The mean age of these patients was 65 years, and 
almost 75% of these patients had received the drug for a 
cardiovascular disorder. Adverse reactions were described 
in 47 patients; 31 were central nervous system disturbances, 
and eight had cardiovascular complications. Significant 
adverse reactions were more frequent in patients with acute 
myocardial infarction and congestive heart failure. Toxicity 
was increasingly frequent in patients with decreased body 
weight and with increasing age but not with serum albumin 
or blood urea nitrogen. This study was performed before the 
widespread use of amiodarone.
Other studies have sought to understand the interaction 
of lidocaine and amiodarone both in vitro and in vivo. In 
laboratory experiments lidocaine metabolism was slowed with 
the inhibition of cytochrome P-4503A4 by amiodarone and its 
metabolite. In six test patients the mean lidocaine clearance 
was decreased by nearly 20 percent when the drugs were co-
administered.7 This interaction would be especially relevant 
when lidocaine accumulates in patients with congestive heart 
failure or hepatic dysfunction.
Our patient appears to fit all the major determinants of 
lidocaine toxicity found in these studies. She was a thin elderly 
woman with previous myocardial infarction, documented 
poor ventricular function, and secondarily decreased hepatic 
clearance. Amiodarone was co-administered, which decreased 
the systemic clearance of lidocaine, leaving this patient 
extremely vulnerable to overdose. 
CONCLUSION
Although amiodarone has replaced lidocaine as the 
medication of choice for stable wide complex tachycardia, 
lidocaine is still widely used. Physicians should be familiar 
with the neurologic and cardiac toxic effects. Risk factors for 
lidocaine toxicity include previous evidence of myocardial 
infarction, congestive heart failure, decreased body weight, 
increased age, and other conditions that affect hepatic 
clearance (Table). Co-administration of amiodarone and 
lidocaine decreases the clearance of lidocaine and may 
increase the risk of toxicity. 
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Table. Factors increasing the likelihood of lidocaine toxicity
Older age • 
Decreased body weight • 
Acute myocardial infarction • 
Congestive heart failure • 
Decreased hepatic function • 
Concomitant use of drugs decreasing P-450 activity (includ- • 
ing amiodarone)